Evidence map›Paper›PMID 34654890›Full record

ArticleScientific reports2021

Prognostic factors and population-based analysis of melanoma with sentinel lymph node biopsy.

Ping-Chung Wu, Yu-Ching Chen, Hsiu-Min Chen, Lee-Wei Chen

Abstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ping-Chung WuDepartment of Surgery, Kaohsiung Veterans General Hospital, No. 386, Da-Zhong 1st Rd., Kaohsiung, Taiwan, Republic of China.
Yu-Ching ChenDepartment of Surgery, Kaohsiung Veterans General Hospital, No. 386, Da-Zhong 1st Rd., Kaohsiung, Taiwan, Republic of China.
Hsiu-Min ChenDepartment of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Lee-Wei ChenDepartment of Surgery, Kaohsiung Veterans General Hospital, No. 386, Da-Zhong 1st Rd., Kaohsiung, Taiwan, Republic of China. lwchen@vghks.gov.tw.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cutaneous malignant melanoma is a rare but fatal disease in East Asia. Despite its increasing incidence, a general lack of awareness about the disease was noted. This study aims to provide population-based prognostic analysis of melanoma with sentinel lymph node biopsy (SLNB) in Taiwan. We conducted this retrospective cohort study using the data from Taiwan National Health Insurance Research Database during 1997-2013. The study cohort contains 3284 patients. The 5-year survival rates of patients undergoing SLNB and not undergoing SLNB were 45.5% and 33.6%. In multivariate analysis, age ≥ 80 years [adjusted hazard ratio (aHR) = 2.15] and male (aHR = 1.19) were associated with a poorer prognosis, while high social economic status (SES) (aHR = 0.69) and undergoing SLNB (aHR = 0.84) were good prognostic factors. Old age and low SES were associated with lower percentages of patients undergoing SLNB (P < 0.001). E-value analysis suggested robustness to unmeasured confounding. In conclusion, undergoing SLNB was associated with a better prognosis. The poor prognosis of old age and low SES may be due to decreased percentages of patients undergoing SLNB. Therefore, we recommend that SLNB should be performed on patients, especially in old age or low SES, who are candidates for SLNB according to current guidelines to achieve maximal survival.

Indexed as

AgedAged, 80 and overComorbidityFemaleHumansMaleMelanomaMiddle AgedPrognosisRetrospective StudiesSentinel Lymph Node BiopsyTaiwan

Identifiers

PMID34654890
PMCPMC8521595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.